Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446720 | 1.00 | MME (0.71) | MMESMN1; SMN2NPSR1KDM1AEPHX2 | |
| SCHEMBL7446011 | 0.92 | MME (0.84) | MMESMN1; SMN2NPSR1KDM1A | |
| SCHEMBL7446007 | 0.92 | MME (0.84) | MMESMN1; SMN2NPSR1KDM1A | |
| SCHEMBL7448568 | 0.91 | MME (0.70) | MMEKDM1A | |
| SCHEMBL7448573 | 0.91 | MME (0.70) | MMEKDM1A | |
| SCHEMBL7450247 | 0.88 | MME (0.59) | MMESMN1; SMN2NPSR1KDM1AEPHX2 | |
| SCHEMBL7453373 | 0.86 | MME (0.67) | MME | |
| SCHEMBL7455180 | 0.86 | MME (0.67) | MME | |
| SCHEMBL7508320 | 0.84 | MME (0.59) | MMESMN1; SMN2NPSR1KDM1AEPHX2 | |
| SCHEMBL7441951 | 0.83 | MME (1.00) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885SMN1; SMN2 2805/4885NPSR1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.